Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality

Nina Singh, Barbara D. Alexander, Olivier Lortholary, Françoise Dromer, Krishan L. Gupta, George T. John, Ramon Del Busto, Goran B. Klintmalm, Jyoti Somani, G. Marshall Lyon, Kenneth Pursell, Valentina Stosor, Patricia Muňoz, Ajit P. Limaye, Andre C. Kalil, Timothy L. Pruett, Julia Garcia-Diaz, Atul Humar, Sally Houston, Andrew A. HouseDannah Wray, Susan Orloff, Lorraine A. Dowdy, Robert A. Fisher, Joseph Heitman, Marilyn M. Wagener, Shahid Husain, Corinne Antoine, Barrou Benoît, Anne Elisabeth Heng, Christophe Legendre, Christian Michelet, Bénédicte Ponceau, Nacéra Ouali, Marc Stern, Theresa Sheppard, Marshall Lyon

Research output: Contribution to journalArticlepeer-review

155 Scopus citations

Abstract

Variables influencing the risk of dissemination and outcome of Cryptococcus neoformans infection were assessed in 111 organ transplant recipients with cryptococcosis in a prospective, multicenter, international study. Sixty-one percent (68/111) of the patients had disseminated infection. The risk of disseminated cryptococcosis was significantly higher for liver transplant recipients (adjusted hazard ratio [HR], 6.65; P = .048). The overall mortality rate at 90 days was 14% (16/111). The mortality rate was higher in patients with abnormal mental status (P = .023), renal failure at baseline (P = .028), fungemia (P = .006), and disseminated infection (P = .035) and was lower in those receiving a calcin eurin-inhibitor agent (P = .003). In a multivariable analysis, the receipt of a calcineurin-inhibitor agent was independently associated with a lower mortality (adjusted HR, 0.21; P = .008), and renal failure at baseline with a higher mortality rate (adjusted HR, 3.14; P = .037). Thus, outcome in transplant recipients with cryptococcosis appears to be influenced by the type of immunosuppressive agent employed. Additionally, discerning the basis for transplant type-specific differences in disease severity has implications relevant for yielding further insights into the pathogenesis of C. neoformans infection in transplant recipients.

Original languageEnglish (US)
Pages (from-to)756-764
Number of pages9
JournalJournal of Infectious Diseases
Volume195
Issue number5
DOIs
StatePublished - Mar 1 2007

Bibliographical note

Funding Information:
Potential conflicts of interest: L.A.D. has received research support from Enzon and Astellas. S. Husain has received research support from Enzon. G.M.L. is on the speaker’s bureaus of Pfizer and Astellas and has received research support from Merck and Astellas. O.L. is on the speaker’s bureaus of Pfizer and Astellas. K.P. is on the speaker’s bureaus for Merck, Pfizer, and Schering-Plough. N.S. has received research grant support from Schering-Plough and Enzon. All other authors report no conflicts of interest.

Funding Information:
Financial support: National Institutes of Health/National Institute of Allergy and Infectious Diseases (award R01 AI054719-01 to N.S.). a Study group members are listed after the text.

Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality'. Together they form a unique fingerprint.

Cite this